Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Operating Income (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Operating Income for 11 consecutive years, with -$119.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Income changed N/A to -$119.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$143.9 million, a N/A change, with the full-year FY2025 number at -$152.6 million, down 281.2% from a year prior.
  • Operating Income was -$119.9 million for Q4 2025 at Crescent Biopharma, down from -$2.4 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$2.4 million in Q1 2025 to a low of -$119.9 million in Q4 2025.
  • A 5-year average of -$18.0 million and a median of -$11.1 million in 2024 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: crashed 76.12% in 2021, then skyrocketed 78.42% in 2025.
  • Crescent Biopharma's Operating Income stood at -$17.4 million in 2021, then surged by 39.04% to -$10.6 million in 2022, then grew by 9.71% to -$9.6 million in 2023, then decreased by 17.13% to -$11.2 million in 2024, then crashed by 967.54% to -$119.9 million in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Operating Income are -$119.9 million (Q4 2025), -$2.4 million (Q1 2025), and -$11.2 million (Q3 2024).